Clinical Trial Update: Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

View source ↗

Summary

Pulmonary function substudy in MannKind MKC-TI-161/162/166 trials has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Status: TERMINATED